Get started
Author

Quyen Duong

Observed name: Q. Duong
OpenAlex ID: A5038800167
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2025 · Patrick M. Forde, Jonathan D. Spicer, et al. · New England Journal of Medicine · 253
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
2024 · Michael Schenker, Mauricio Burotto, et al. · Journal for ImmunoTherapy of Cancer · 41
PDF
Principles of Good Clinical Trial Design
2020 · Ming-Wen An, Quyen Duong, et al. · Journal of Thoracic Oncology · 25
Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials
2020 · Quyen Duong, Sumithra J. Mandrekar, et al. · Journal of Cancer Education · 12
Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.
2025 · Patrick M. Forde, Jonathan Spicer, et al. · Journal of Clinical Oncology · 11
PDF
Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms
2021 · Yahya Almodallal, Quyen Duong, et al. · JCO Oncology Practice · 3
Long-term outcomes of neoadjuvant nivolumab plus chemotherapy in resectable NSCLC in Japanese patients: final 5-year follow-up analysis from CheckMate 816
2026 · Tetsuya Mitsudomi, Yasuhiro Tsutani, et al. · International Journal of Lung Cancer
Nivolumab vs placebo dans le traitement adjuvant des patients atteints d’un mélanome de stade IIB/C : résultats à 4 ans de l’étude CheckMate 76K (CM 76K)
2025 · J.M. Kirkwood, M. Del Vecchio, et al. · Annales de Dermatologie et de Vénéréologie - FMC
Works count: 8
Citation count: 344
H-index: 5
I10-index: 5
Year
Topic
Type